Abstract |
Lanreotide Autogel (ATG) [ Somatuline Depot]The use of trade names is for product identification purposes only and does not imply endorsement. is a novel, long-acting preparation of the somatostatin analog lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I ( IGF-I) levels. It is indicated for the management of acromegaly and, relative to most other licensed agents, it has a favorable pharmacokinetic profile that permits administration once every 28-42 days. Subcutaneous lanreotide ATG was an effective and generally well tolerated treatment in patients with acromegaly in well designed trials and extension studies of up to 4 years' duration. It was shown to be no less effective than intramuscular lanreotide long-acting (LA) microparticle treatment in these studies, with more limited data showing that lanreotide ATG therapy was as effective as intramuscular octreotide long-acting repeating ( octreotide LAR) treatment. While both of these latter agents offer the advantage of treatment once every 28 days, lanreotide ATG also has the advantage of being available in a convenient pre-filled syringe and is given subcutaneously rather than intramuscularly like other somatostatin analogs. Thus it provides a valuable first-line option for the management of patients with acromegaly.
|
Authors | Jamie D Croxtall, Lesley J Scott |
Journal | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
(BioDrugs)
Vol. 22
Issue 4
Pg. 275-7
( 2008)
ISSN: 1173-8804 [Print] New Zealand |
PMID | 18611070
(Publication Type: Journal Article)
|
Chemical References |
- Delayed-Action Preparations
- Peptides, Cyclic
- lanreotide
- Somatostatin
|
Topics |
- Acromegaly
(drug therapy)
- Delayed-Action Preparations
- Humans
- Peptides, Cyclic
(administration & dosage, adverse effects, therapeutic use)
- Somatostatin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
|